A randomized controlled trial to evaluate the effect of contrast material dilution on renal function in patients with lower extremity artery disease after endovascular revascularization

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078170

Enrollment

Unknown

Registered

2023-11-30

Start date

2023-11-30

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower extremity artery disease

Interventions

Contrast dilution group:Dilute the contrast medium

stock solution group:Conventional contrast agents

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with lower extremity arterial disease (including thromboangiitis obliterans, lower extremity arteriosclerotic obliterans, acute lower extremity arterial embolism, etc.) and scheduled to undergo endovascular repair of lower extremity

Exclusion criteria

Exclusion criteria: ? Patients who refused to participate in the trial; ? Chronic renal insufficiency stage 4 to 5; ? Patients allergic to contrast agents

Design outcomes

Primary

Measure	Time frame
renal function;The success rate and clinical success rate of target vessel opening technology;	—

Secondary

Measure	Time frame
VAS score (maximum and duration of VAS for intraoperative pain);Adverse events and mortality within 30 days;	—

Countries

China

Contacts

Public ContactZhao Jichun

West China Hospital of Sichuan University

cgx9571@163.com+86 178 8233 2790

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026